Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Initial Experience of Tomosynthesis-Guided Vacuum-Assisted Biopsies of Tomosynthesis-Detected (2D Mammography and Ultrasound Occult) Architectural Distortions.

Patel BK, Covington M, Pizzitola VJ, Lorans R, Giurescu M, Eversman W, Lewin J.

AJR Am J Roentgenol. 2018 Jun;210(6):1395-1400. doi: 10.2214/AJR.17.18802. Epub 2018 Mar 23.

PMID:
29570367
2.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL.

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4.

PMID:
28976790
3.

Operative outcomes of conventional specimen radiography versus in-operating room specimen radiography in radioactive seed-localized segmental mastectomies.

Rhee D, Pockaj B, Wasif N, Stucky CC, Pizzitola V, Giurescu M, Patel B, McCarthy J, Gray R.

Am J Surg. 2018 Jan;215(1):151-154. doi: 10.1016/j.amjsurg.2017.07.019. Epub 2017 Jul 19.

PMID:
28784236
4.

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.

Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbatchevsky I, Liu L, Koechert K, Peña C, Neves M, Childs BH, Zinzani PL.

Ann Oncol. 2017 Sep 1;28(9):2169-2178. doi: 10.1093/annonc/mdx289.

5.

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.

Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH.

Target Oncol. 2017 Feb;12(1):97-109. doi: 10.1007/s11523-016-0469-y.

PMID:
27975152
6.

Contrast-enhanced Digital Mammography: A Single-Institution Experience of the First 208 Cases.

Lewis TC, Pizzitola VJ, Giurescu ME, Eversman WG, Lorans R, Robinson KA, Patel BK.

Breast J. 2017 Jan;23(1):67-76. doi: 10.1111/tbj.12681. Epub 2016 Oct 2.

PMID:
27696576
7.

Validation study of a modern treatment algorithm for nipple discharge.

Ashfaq A, Senior D, Pockaj BA, Wasif N, Pizzitola VJ, Giurescu ME, Gray RJ.

Am J Surg. 2014 Aug;208(2):222-7. doi: 10.1016/j.amjsurg.2013.12.035. Epub 2014 Apr 3.

PMID:
24767970
8.

Papillary lesions on core breast biopsy: excisional biopsy for all patients?

McGhan LJ, Pockaj BA, Wasif N, Giurescu ME, McCullough AE, Gray RJ.

Am Surg. 2013 Dec;79(12):1238-42.

PMID:
24351348
9.

Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer.

Gauler TC, Christoph DC, Fischer J, Frickhofen N, Huber R, Gonschorek C, Roth K, Giurescu M, Eberhardt WE.

Eur J Cancer. 2013 Jul;49(11):2461-8. doi: 10.1016/j.ejca.2013.03.029. Epub 2013 May 18.

PMID:
23692812
10.

Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy?

McGhan LJ, Pockaj BA, Wasif N, Giurescu ME, McCullough AE, Gray RJ.

Ann Surg Oncol. 2012 Oct;19(10):3264-9. doi: 10.1245/s10434-012-2575-0. Epub 2012 Aug 10.

PMID:
22878619
11.

Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.

Beer TM, Smith DC, Hussain A, Alonso M, Wang J, Giurescu M, Roth K, Wang Y.

Br J Cancer. 2012 Aug 21;107(5):808-13. doi: 10.1038/bjc.2012.339. Epub 2012 Jul 31.

12.

Clinical and self breast examination remain important in the era of modern screening.

Ma I, Dueck A, Gray R, Wasif N, Giurescu M, Lorans R, Pizzitola V, Pockaj B.

Ann Surg Oncol. 2012 May;19(5):1484-90. doi: 10.1245/s10434-011-2162-9. Epub 2011 Dec 8.

PMID:
22160521
13.

Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.

McMeekin S, Patel R, Verschraegen C, Celano P, Burke J 2nd, Plaxe S, Ghatage P, Giurescu M, Stredder C, Wang Y, Schmelter T.

Br J Cancer. 2012 Jan 3;106(1):70-6. doi: 10.1038/bjc.2011.499. Epub 2011 Nov 22.

14.

Radioactive seed localization for nonpalpable breast lesions: review of 1,000 consecutive procedures at a single institution.

McGhan LJ, McKeever SC, Pockaj BA, Wasif N, Giurescu ME, Walton HA, Gray RJ.

Ann Surg Oncol. 2011 Oct;18(11):3096-101. doi: 10.1245/s10434-011-1910-1. Epub 2011 Sep 27.

PMID:
21947587
15.

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.

Rustin G, Reed N, Jayson GC, Ledermann JA, Adams M, Perren T, Poole C, Lind M, Persic M, Essapen S, Gore M, Calvert H, Stredder C, Wagner A, Giurescu M, Kaye S.

Ann Oncol. 2011 Nov;22(11):2411-6. doi: 10.1093/annonc/mdq780. Epub 2011 Mar 3.

PMID:
21372124
16.

Use of preoperative magnetic resonance imaging for invasive lobular cancer: good, better, but maybe not the best?

McGhan LJ, Wasif N, Gray RJ, Giurescu ME, Pizzitola VJ, Lorans R, Ocal IT, Stucky CC, Pockaj BA.

Ann Surg Oncol. 2010 Oct;17 Suppl 3:255-62. doi: 10.1245/s10434-010-1266-y. Epub 2010 Sep 19.

PMID:
20853043
17.

Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.

Morrow PK, Divers S, Provencher L, Luoh SW, Petrella TM, Giurescu M, Schmelter T, Wang Y, Hortobagyi GN, Vahdat LT.

Breast Cancer Res Treat. 2010 Oct;123(3):837-42. doi: 10.1007/s10549-010-1102-x. Epub 2010 Aug 10.

PMID:
20697802
18.

Role of imaging in breast cancer detection.

Giurescu ME, Hu T, Obembe O.

AAOHN J. 2010 Apr;58(4):131-4. doi: 10.3928/08910162-20100329-02.

PMID:
20415340
19.

Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors.

Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H, Thiel E, Kühnhardt D.

Ann Oncol. 2010 Mar;21(3):633-9. doi: 10.1093/annonc/mdp491. Epub 2009 Oct 30.

PMID:
19880436
20.

Does magnetic resonance imaging accurately predict residual disease in breast cancer?

Stucky CC, McLaughlin SA, Dueck AC, Gray RJ, Giurescu ME, Carpenter SG, Grimsby GM, Apsey HA, Pockaj BA.

Am J Surg. 2009 Oct;198(4):547-52. doi: 10.1016/j.amjsurg.2009.04.008.

PMID:
19800466
21.

Is there concordance of invasive breast cancer pathologic tumor size with magnetic resonance imaging?

Grimsby GM, Gray R, Dueck A, Carpenter S, Stucky CC, Aspey H, Giurescu ME, Pockaj B.

Am J Surg. 2009 Oct;198(4):500-4. doi: 10.1016/j.amjsurg.2009.07.012.

PMID:
19800455
22.

Scientific Presentation Award: The impact of magnetic resonance imaging on surgical treatment of invasive breast cancer.

Carpenter SG, Stucky CC, Dueck AC, Grimsby G, Giurescu M, Apsey H, Gray RJ, Pockaj BA.

Am J Surg. 2009 Oct;198(4):475-81. doi: 10.1016/j.amjsurg.2009.06.015.

PMID:
19800451
23.

Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial.

Arnold D, Voigt W, Kiewe P, Behrmann C, Lindemann S, Reif S, Wiesinger H, Giurescu M, Thiel E, Schmoll HJ.

Br J Cancer. 2009 Oct 20;101(8):1241-7. doi: 10.1038/sj.bjc.6605327. Epub 2009 Sep 22.

24.

Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate.

Klar U, Hoffmann J, Giurescu M.

Expert Opin Investig Drugs. 2008 Nov;17(11):1735-48. doi: 10.1517/13543784.17.11.1735 . Review.

PMID:
18922109
25.

Influence of treatment with onapristone on the IGF-system in breast cancer patients.

Helle SI, Jonat W, Giurescu M, Ekse D, Holly JM, Lønning PE.

J Steroid Biochem Mol Biol. 1998 Aug;66(3):159-63.

PMID:
9719450
26.

Clinical importance of unilaterally enlarging lymph nodes on otherwise normal mammograms.

Lee CH, Giurescu ME, Philpotts LE, Horvath LJ, Tocino I.

Radiology. 1997 May;203(2):329-34.

PMID:
9114083

Supplemental Content

Loading ...
Support Center